Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • QE2
  • Latest news
  • Worldwide impact of NIBSC
  • Mission and values
  • Careers
  • Quality and governance
  • Staff profiles
  • Contact us
  • Collaborations
  • Suppliers
  • Scientific Advisory Committee
  • Minutes of the Animal Welfare and Ethical Review Body
  • Our use of animals
  • Privacy notice
  • Home  /  
  • About us

About us

  • Control testing of biological medicines
  • Biological standards and reference materials
  • Applied research
  • Our work with the World Health Organisation (WHO)
  • NIBSC Management

The National Institute for Biological Standards and Control (NIBSC) plays a major national and international role in assuring the quality of biological medicines through:

  • developing standards and reference materials
  • product control testing
  • carrying out applied research

We play a key role in providing scientific advice and expertise to a large number of organisations, including:

  • manufacturers of biological medicines
  • national regulatory authorities
  • the UK government and European bodies
  • the World Health Organisation
  • UN agencies

Contributions from NIBSC scientists, as members of key decision-making bodies at both European and international level, feed into the development of national and international policies that help to ensure the safety and efficacy of biological medicines.

We serve a broad range of customers and stakeholders in the UK and abroad and have a worldwide reputation for independence, integrity and scientific excellence.

Control testing of biological medicines

The Institute is the UK’s National Control Laboratory, responsible for carrying out Independent Control Testing as required by UK law. 

Biological medicines and vaccines are usually very complex materials. In order to ensure that these products are both safe and effective it is necessary to thoroughly evaluate their quality and biological activity. Each batch is examined and approved, independently from the manufacturers, and issued with a certificate before being released onto the market.

Biological substances used in healthcare include bacterial and viral vaccines against diseases such as: 

  • diphtheria
  • whooping-cough
  • meningitis
  • poliomyelitis
  • influenza
  • hepatitis
  • measles
  • mumps
  • rubella 

They also include therapeutic products derived from human blood such as clotting factors and immunoglobulins, as well as other products such as monoclonal antibodies, hormones, cytokines and growth factors. 

We work closely with MHRA and other European regulators for this work.

Biological standards and reference materials

We have a leading international role in preparing, evaluating and distributing international biological standards and other biological reference materials, supplying over 90% of these for the World Health Organisation (WHO). The complex assays used to assure the potency of biologicals require the use of a standard of biological activity - a batch of substance that has been assigned units of activity and is used as a ’benchmark’.

The effective use of vaccines, most biotechnology products in therapy and many other biologicals depends on the availability of international biological standards supplied by NIBSC.

In addition to standards for WHO, NIBSC holds over 2,000 reagents managed by the Centre for AIDS Reagents (CFAR). The CJD Resource Centre supplies characterised materials for studying and developing diagnostic tests for Creutzfeldt-Jakob Disease (CJD).

Applied research

NIBSC carries out an active high-quality research programme directly related to its strategic aims, carried out by internationally respected scientists, attracting significant external funding and generating an impressive publication output.

Through the Institute’s testing and evaluation activities, NIBSC’s scientists help to ensure the safety and efficacy of biological products while helping to minimise the time taken to bring new products into clinical use. New products have needed novel approaches for their control and development of new testing methods. You will find more information about the wide range of research activities that we carry out in the science and research pages. The vast potential increase in the numbers and complexity of biologicals, as a result of the genomics revolution will demand further developments in testing methods and strategies. 

Our work with the World Health Organisation (WHO)

We are the leading WHO Collaborating Centre and International Laboratory for Biological Standards, Essential Regulatory Laboratory (ERL) for Influenza, WHO Collaborating Centre for Reference & Research on Poliomyelitis and the WHO Global Specialised Polio Network Laboratory.

We occupy a unique international position as the interface between:

  • product manufacturers
  • regulators
  • policy makers
  • cutting-edge academic research

NIBSC Management

The Senior Management Team is composed of the following NIBSC staff, supported by the MHRA Corporate Services Divisions: Finance, Human Resources, Communications and Information Management.

  • Dr Marc Bailey, Interim Director
  • Dr Neil Almond, Head of Infectious Disease Diagnostics
  • Dr Paul Bowyer, Acting Head of Analytical and Biological Sciences
  • Dr Chris Burns, Head of Biotherapeutics 
  • Penny Carter, Agency Head of Infrastructure and Operations
  • Marie Donatantonio, Head of NIBSC Corporate Affairs
  • Dr Nicola Rose, Head of Virology
  • Dr Paul Stickings, Acting Head of Bacteriology
  • Alison James, Head of Standards Processing Division
  • Amanda King, Head of Business Development
  • Dr Elsa Abranches, Acting Head of Advanced Therapies
 
 
 
  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap